NVONOVO NORDISK A S

NYSE novonordisk.com


$ 143.07 $ -0.20 (-0.14 %)    

Friday, 07-Jun-2024 11:36:27 EDT
QQQ $ 463.61 $ 2.06 (0.45 %)
DIA $ 390.15 $ 2.14 (0.55 %)
SPY $ 534.88 $ 1.56 (0.29 %)
TLT $ 91.72 $ 0.10 (0.11 %)
GLD $ 213.49 $ -0.80 (-0.37 %)
$ 142.4
$ 143.27
$ 115.00 x 181
$ 0.00 x 0
$ 142.27 - $ 143.72
$ 74.66 - $ 142.94
4,369,174
na
642,224
$ 0.65
$ 0.00
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 etfs-bet-high-on-weight-loss-drugs-but-industry-observers-question-long-term-potential

New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and t...

 ozempic-wegovy-create-domino-effect-as-new-products-emerge-across-industries-to-capture-new-consumer-habits

Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shift...

 british-agency-supports-eli-lillys-weight-loss-drug-mounjaro-diverging-from-restrictions-on-rival-novo-nordisks-wegovy

NICE recommends Eli Lilly's Mounjaro for obesity, omitting time limits applied to Novo Nordisk's Wegovy, opening new av...

Core News & Articles

- Reuters

 novo-nordisk-sues-additional-us-clinics-against-fake-semaglutide-products-used-for-weight-loss-diabetes

Novo Nordisk has filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling impure ...

 new-weight-loss-etf-is-essentially-a-play-on-eli-lilly-novo-nordisk

New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, w...

 weight-loss-drug-market-to-rocket-to-130b-by-2030-with-eli-lilly-novo-nordisk-in-lead-goldman-sachs

Goldman Sachs re-rated Eli Lilly and Novo Nordisk, citing potential for weight-loss drugs. Global sales expected to reach $130B...

 jim-cramer-recommends-buying-apple-finds-this-tech-stock-very-interesting

On CNBC's "Mad Money Lightning Round," Jim Cramer said Apple Inc. is a "buy" after iPhone sales in China sa...

 weight-loss-drug-forecasts-skyrocket-to-150b-as-novo-nordisk-eli-lilly-ramp-up-supply

The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increa...

 novo-nordisk-faces-scrutiny-over-high-prices-of-ozempic-and-wegovy-blames-us-health-system

Novo Nordisk retains around 60% of the list price for its diabetes and obesity medications, Ozempic and Wegovy, after rebates a...

 ozempic-maker-novo-nordisks-increasing-influence-on-denmarks-employment-raises-economic-concerns

The updated employment figures have heightened concerns about Denmark's economy becoming excessively dependent on Novo.

 european-equities-close-higher-as-traders-bank-on-imminent-ecb-rate-cut-whats-driving-markets-monday

European equities up, ECB likely to cut rates in June, traders confident. Euro slightly higher. Top performers: RWE, Bayer, VW,...

 chinese-scientists-achieve-worlds-first-diabetes-cure-using-cell-therapy-report

A team of Chinese scientists has successfully cured a patient's diabetes using cell therapy, marking a global first.

 elon-musk-says-ozempic-will-become-very-cheap-after-new-comedy-special-paints-it-as-weight-loss-drug-only-wealthy-people-can-afford

Elon Musk predicts that Novo Nordisk's weight-loss drug Ozempic will eventually become very cheap, following its depiction ...

Core News & Articles

- Bloomberg TV Interview

 novo-nordisk-releases-data-showing-ozempic-for-diabetes-slows-kidney-disease-progression

Novo Nordisk's Ozempic was used on 3,533 patients; results show a 24% reduction in kidney disease progression.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION